KMDA

KMDA

USD

Kamada Ltd. Ordinary Shares

$6.670-0.220 (-3.193%)

リアルタイム価格

Healthcare
Drug Manufacturers - Specialty & Generic
イスラエル

価格チャート

Loading Chart...

主要指標

市場指標
企業ファンダメンタルズ
取引統計

市場指標

始値

$6.890

高値

$6.890

安値

$6.660

出来高

0.03M

企業ファンダメンタルズ

時価総額

386.0M

業種

Drug Manufacturers - Specialty & Generic

Israel

取引統計

平均出来高

0.06M

取引所

NMS

通貨

USD

52週レンジ

安値 $5.54現在値 $6.670高値 $9.15

AI分析レポート

最終更新: 2025年10月13日
AIによる生成データソース: Yahoo Finance, Bloomberg, SEC

KMDA's Pulse Quickens: Data Points to a Short-Term Surge for Kamada

October 13, 2025, 08:31 AM EDT

Whispers in the Headlines

The news stream around Kamada has been quiet lately, but the key events from late summer tell an important story. Back on August 11th, the company announced a solid operational win: FDA approval for its new plasma collection center in Houston. This is a tangible piece of good news that expands the company's capacity. Just two days later, the company held its Q2 earnings call. While the transcript itself is just a record, the timing is interesting. That day, August 13th, saw a huge spike in trading volume and a wide price swing, suggesting the market was reacting strongly to the financial results and commentary. These past events seem to be setting the stage for the current market mood.

The Anatomy of a Downturn

Looking at Kamada's stock chart over the last three months is like watching a slow, grinding descent. The shares tumbled from a peak above $8.00 in mid-July, falling steadily through August and September. The price eventually found a floor, bouncing multiple times in the $6.50 to $6.70 range. This area appears to be a new level of support where buyers have consistently stepped in.

The most recent price action shows a potential change in character. After hitting a low of $6.50 on October 7th, the stock has started to claw its way back up, closing the latest session at $6.80. This stabilization, after a long period of selling, is often the first sign that the balance of power might be shifting from sellers back to buyers.

The Digital Crystal Ball

The current technical picture is where things get compelling. Several indicators are flashing green, suggesting a bullish turn. We're seeing a "golden cross" in the MACD indicator, a classic signal that momentum is shifting upward. Trading volume has also surged, which confirms there's real conviction behind the recent price moves. On top of that, our AI model is forecasting a price jump of nearly 4% over the next three days with a high degree of confidence.

However, it's important to weigh this against the company's financial health. The fundamental data points to some real challenges, including very high debt and low revenue growth. This creates a clear conflict: the short-term technicals and AI predictions look strong, but the long-term business fundamentals appear weak. This suggests any current opportunity is likely a short-term trade, not a long-term investment.

The Bottom Line

For traders with a moderate appetite for risk, the data suggests a short-term opportunity in Kamada (KMDA) may be forming. The combination of a potential bottom in the stock price, strong technical buy signals, and a bullish AI forecast creates a compelling case for a quick trade over the next one to two weeks. The weak fundamentals, however, mean this is not a "buy and hold" situation.

A strategic approach could involve entering a position around the $6.77 - $6.83 levels. Given the stock's recent volatility and underlying risks, setting a firm stop-loss at $6.12 is critical to protect against a reversal. If the bullish momentum continues as the data suggests, a reasonable target to take profits would be near $7.29.


Disclaimer: This report is for informational purposes only and does not constitute financial advice, an offer to sell, or a solicitation of an offer to buy any security. The analysis is based solely on the structured data provided and may not be comprehensive. Investing in stocks involves risks, including the possible loss of principal. You should always conduct your own research and consult with a qualified financial advisor before making any investment decisions.

関連ニュース

GlobeNewswire

Kamada Reports Strong Third Quarter and Nine Month 2025 Financial Results with over 30% Year-over-Year Profitability Growth

Third Quarter Revenues of $47.0 Million, up 13% Year-over-Year, and Adjusted EBITDA of $11.7 Million, up 34% Year-Over YearNine Month Revenue of $135.8 Million, up 11% Year-over-Year; Adjusted EBITDA of $34.2 Million, up

もっと見る
Kamada Reports Strong Third Quarter and Nine Month 2025 Financial Results with over 30% Year-over-Year Profitability Growth
GlobeNewswire

Kamada to Announce Third Quarter and Nine Months Ended September 30, 2025 Financial Results on November 10, 2025

REHOVOT, Israel and HOBOKEN, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA)), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for

もっと見る
Kamada to Announce Third Quarter and Nine Months Ended September 30, 2025 Financial Results on November 10, 2025
GlobeNewswire

Kamada to Present at the Stifel 2025 Healthcare Conference

REHOVOT, Israel and Hoboken, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA)), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious

もっと見る
Kamada to Present at the Stifel 2025 Healthcare Conference

AI予測Beta

AI推奨

強気

更新日時: 2025年11月10日 12:05

弱気中立強気

65.5% 信頼度

リスクと取引

リスクレベル3/5
中リスク
適しているのは
中程度
取引ガイド

エントリーポイント

$6.61

利確

$7.17

損切り

$6.02

主要因子

RSIは71.4で、買われすぎ状態を示しています
PDI 13.8はMDI 5.4の上にあり、ADX 11.8とともに強気トレンドを示唆しています
現在の価格はサポートレベル(6.61ドル)に非常に接近しており、強力な買い機会を示唆しています
出来高は平均(1,593)の2.6倍で、 significant buying interest(大幅な買い意欲)を示しています
MACD 0.0059はシグナルライン-0.0033の上にあり、強気クロスオーバーを示しています

最新情報を入手

価格アラートを設定し、AI分析の更新とリアルタイム市場ニュースを受け取る。